

Jérémy BALLAND¹, Aurélie BADILLO², Philippe DULIEU^{1,2}, Laurence RINGENBACH¹, Pierre-Emmanuel BAURAND¹

¹Diaclone S.A.S., 6 Rue Dr Jean-François-Xavier Girod, BP 1985, F-25020 Besançon Cedex, France - ²RD-Biotech, 3 rue Baigue F-25000 Besançon






I/ INTRODUCTION

- Since 1991 → 6 fusions carried out giving only one specific anti-IL-8 mAb : clone B-K8, used in Diaclone's IL-8 ELISA kit paired with a rabbit polyclonal.

The aim of this project was to replace the polyclonal by a new anti-IL-8 Mab


- In 2019 → New mouse immunization to run in parallel classical fusion method and phage display approach.
After Fusion → 490 candidates tested → 0 positive

III/ PHAGE DISPLAY METHOD



III/ RESULTS AND CONCLUSION

- 7 Fab Candidates selected from 96 screened
→ The best candidate :
 - is IL-8 specific (Fig 5)
 - paired with the B-K8 (Fig 5)
- Reformatting in full IgG1
→ validated in Elisa kit and named **B-B49** (Fig 6)



Phage display technology allows mAb development particularly difficult to obtain with a classical fusion